Abiomed, Inc.
ABMD · NASDAQ
3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 21.7% | 0.8% | 9.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 81.8% | 80.9% | 82% | 83.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 36.1% | 27.1% | 29.6% | 29.2% |
| Other Income/Exp. Net | -$0 | $0 | $0 | $0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 13.2% | 26.6% | 24.1% | 33.7% |
| EPS | 3 | 5 | 4.49 | 5.77 |
| % Growth | -40% | 11.4% | -22.2% | – |
| EPS Diluted | 2.98 | 4.94 | 4.43 | 5.61 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 48.5% | 29.1% | 30.6% | 30% |